Conjugated vaccines: from the laboratory to pilot scale 3

• Grant number: 06/06735-9
• Support Opportunities: Regular Research Grants
• Start date: May 01, 2007
• End date: October 31, 2009
• Field of knowledge: Biological Sciences - Biochemistry - Chemistry of Macromolecules
• Principal Investigator: Martha Massako Tanizaki
• Grantee: Martha Massako Tanizaki
• Host Institution: Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Vaccines against capsulated bacteria currently used worldwide are denominated conjugate vaccines which are constituted by the capsular polysaccharide conjugated to a protein. The aims of this project are: 1. development of a vaccine against Haemophilus influenzae type, capsular polysaccharide conjugated to tetanus toxoid by a scaleable- up process. 2. Test of a conjugate vaccine against Streptococcus pneumoniae constituted by the capsular polysaccharide conjugated to a pneumococcal membrane protein (PspA). The aim of the An improved method to calculate antibody avidity index.use of the protein PspA is to increase the coverage of the conjugate vaccine. At least, two different serotype polysaccharides will be tested: 23F and 6 B and two different PspA: family 1 and 3. The project includes also optimization of the cultivation process of the S.pneumoniae 6B and E. coli expressing PspA. (AU)